Compendium of Cancer Genome Aberrations

HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract: Difference between revisions

[checked revision][checked revision]
← Older edit
VisualWikitext
No edit summary
No edit summary
 
(4 intermediate revisions by the same user not shown)
Line 4: Line 4:
{{Under Construction}}
{{Under Construction}}


<blockquote class='blockedit'>{{Box-round|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract]].
<blockquote class="blockedit">{{Box-round|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract]].
}}</blockquote>
}}</blockquote>


Line 12: Line 12:


Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
__TOC__
==WHO Classification of Disease==
==WHO Classification of Disease==


Line 37: Line 34:
|}
|}


==Definition / Description of Disease==
==Related Terminology==
 
 
*Indolent T-cell lymphoproliferative disorders of the gastrointestinal tract (GI TLPD) are rare neoplasms that mimic intestinal T-cell lymphoma and other inflammatory diseases of the GI tract, including Crohn's disease. However, it has distinct cellular derivation, pathobiological features and genomic landscape that remains to be fully elucidated
 
 
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref name=":1">{{Cite journal|last=E|first=Margolskee|last2=V|first2=Jobanputra|last3=Sk|first3=Lewis|last4=B|first4=Alobeid|last5=Ph|first5=Green|last6=G|first6=Bhagat|date=2013|title=Indolent small intestinal CD4+ T-cell lymphoma is a distinct entity with unique biologic and clinical features|url=https://pubmed.ncbi.nlm.nih.gov/23861889/|language=en|doi=10.1371/journal.pone.0068343|pmc=PMC3701677|pmid=23861889}}</ref><blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
</blockquote>
==Synonyms / Terminology==
 
*N/A
 
==Epidemiology / Prevalence==
 
 
*Extremely rare
*Etiology not understood, but some have a history of Crohn disease
 
 
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref name=":2">{{Cite journal|last=Am|first=Perry|last2=Ra|first2=Warnke|last3=Q|first3=Hu|last4=P|first4=Gaulard|last5=C|first5=Copie-Bergman|last6=S|first6=Alkan|last7=Hy|first7=Wang|last8=Jx|first8=Cheng|last9=Cm|first9=Bacon|date=2013|title=Indolent T-cell lymphoproliferative disease of the gastrointestinal tract|url=https://pubmed.ncbi.nlm.nih.gov/24009234/|language=en|doi=10.1182/blood-2013-07-512830|pmc=PMC3837508|pmid=24009234}}</ref><blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
</blockquote>
==Clinical Features==
 
Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table. Do not delete table.'') </span>
{| class="wikitable"
|'''Signs and Symptoms'''
|<span class="blue-text">EXAMPLE:</span> Asymptomatic (incidental finding on complete blood counts)
 
<span class="blue-text">EXAMPLE:</span> B-symptoms (weight loss, fever, night sweats)
 
<span class="blue-text">EXAMPLE:</span> Fatigue
 
<span class="blue-text">EXAMPLE:</span> Lymphadenopathy (uncommon)
|-
|'''Laboratory Findings'''
|<span class="blue-text">EXAMPLE:</span> Cytopenias
 
<span class="blue-text">EXAMPLE:</span> Lymphocytosis (low level)
|}
 
 
<blockquote class='blockedit'>{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}}</blockquote>
 
*Abdominal pain
*Diarrhea
*Dyspepsia
*Weight loss
*Endoscopic findings:
**Thickened, nodular, hyperemic mucosal surface with superficial erosions
**If presenting as intestinal polyps, may mimic lymphomatous polyposis
*No association with celiac disease
 
'''ADD REF'''
 
<blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
</blockquote>
==Sites of Involvement==
 
*Small intestine and colon (predominant)
*Any gastrointestinal mucosa possible
*May present as polypoid lesions in the stomach, duodenum, terminal ileum and colon<ref>{{Cite journal|last=K|first=Hirakawa|last2=T|first2=Fuchigami|last3=S|first3=Nakamura|last4=Y|first4=Daimaru|last5=K|first5=Ohshima|last6=Y|first6=Sakai|last7=T|first7=Ichimaru|date=1996|title=Primary gastrointestinal T-cell lymphoma resembling multiple lymphomatous polyposis|url=https://pubmed.ncbi.nlm.nih.gov/8780585/|language=en|pmid=8780585}}</ref>
 
==Morphologic Features==
 
*Small, monotonous, round, lymphocytes with scant cytoplasm
*Lymphoid infiltrate expands lamina propria and displaces mucosal glands, but does not cause destruction of underlying architecture, and usually does not invade epithelium
*Admixed inflammatory cells are uncommon
 
'''ADD REF'''
 
==Immunophenotype==
 
 
{| class="wikitable sortable"
|-
!Finding!!Marker
|-
|Positive (universal)||CD3, CD2, CD5, TIA1 (in CD8+ cases), TCR alpha beta
|-
|Positive (frequent)||CD8 > CD4
|-
|Positive (rare)
|CD4+CD8+ (double positive)
|-
|Negative (universal)||TCR-gamma, EBER, NKp46, CD56
|-
|Negative (frequent)
|Granzyme B, CD103
|-
|Negative (rare)||CD4-CD8- (double negative)
|-
|Ki-67
|< 10%
|}
 


<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref name=":1" /><ref name=":3">{{Cite journal|last=M|first=Cheminant|last2=J|first2=Bruneau|last3=G|first3=Malamut|last4=D|first4=Sibon|last5=N|first5=Guegan|last6=T|first6=van Gils|last7=S|first7=Cording|last8=A|first8=Trinquand|last9=V|first9=Verkarre|date=2019|title=NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study|url=https://pubmed.ncbi.nlm.nih.gov/30448772/|language=en|pmid=30448772}}</ref><blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
</blockquote>
==WHO Essential and Desirable Genetic Diagnostic Criteria==
<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
{| class="wikitable"
|+
|WHO Essential Criteria (Genetics)*
|
|-
|WHO Desirable Criteria (Genetics)*
|
|-
|Other Classification
|
|}
<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
==Related Terminology==
<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>
{| class="wikitable"
{| class="wikitable"
|+
|+
|Acceptable
|Acceptable
|
|Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract; indolent clonal T-cell lymphoproliferative disorder of the gastrointestinal tract
|-
|-
|Not Recommended
|Not Recommended
|
|N/A
|}
|}


Line 231: Line 108:
|}
|}


<blockquote class='blockedit'>{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}</blockquote>
<blockquote class="blockedit">{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}</blockquote>




Line 244: Line 121:
|}
|}


<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref name=":0">{{Cite journal|last=A|first=Sharma|last2=N|first2=Oishi|last3=Rl|first3=Boddicker|last4=G|first4=Hu|last5=Hk|first5=Benson|last6=Rp|first6=Ketterling|last7=Pt|first7=Greipp|last8=Dl|first8=Knutson|last9=Sm|first9=Kloft-Nelson|date=2018|title=Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract|url=https://pubmed.ncbi.nlm.nih.gov/29592893/|language=en|doi=10.1182/blood-2018-01-830968|pmc=PMC5958657|pmid=29592893}}</ref><blockquote class="blockedit">
<blockquote class="blockedit">{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref name=":0">{{Cite journal|last=A|first=Sharma|last2=N|first2=Oishi|last3=Rl|first3=Boddicker|last4=G|first4=Hu|last5=Hk|first5=Benson|last6=Rp|first6=Ketterling|last7=Pt|first7=Greipp|last8=Dl|first8=Knutson|last9=Sm|first9=Kloft-Nelson|date=2018|title=Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract|url=https://pubmed.ncbi.nlm.nih.gov/29592893/|language=en|doi=10.1182/blood-2018-01-830968|pmc=PMC5958657|pmid=29592893}}</ref><blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
----
Line 254: Line 131:




<blockquote class='blockedit'>{{Box-round|title=v4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).|Please incorporate this section into the relevant tables found in:
<blockquote class="blockedit">{{Box-round|title=v4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).|Please incorporate this section into the relevant tables found in:
* Chromosomal Rearrangements (Gene Fusions)
* Chromosomal Rearrangements (Gene Fusions)
* Individual Region Genomic Gain/Loss/LOH
* Individual Region Genomic Gain/Loss/LOH
Line 292: Line 169:
|NKp46
|NKp46
|Possible role in diagnosis (exclusion)
|Possible role in diagnosis (exclusion)
|Positive stain does not favor the diagnosis<ref name=":3" /> but seen in type 2 refractory celiac disease, EATL and MEITL
|Positive stain does not favor the diagnosis<ref name=":3">{{Cite journal|last=M|first=Cheminant|last2=J|first2=Bruneau|last3=G|first3=Malamut|last4=D|first4=Sibon|last5=N|first5=Guegan|last6=T|first6=van Gils|last7=S|first7=Cording|last8=A|first8=Trinquand|last9=V|first9=Verkarre|date=2019|title=NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study|url=https://pubmed.ncbi.nlm.nih.gov/30448772/|language=en|pmid=30448772}}</ref> but seen in type 2 refractory celiac disease, EATL and MEITL
|}
|}


*'''Prognosis'''<ref name=":2" />
*'''Prognosis'''<ref name=":2">{{Cite journal|last=Am|first=Perry|last2=Ra|first2=Warnke|last3=Q|first3=Hu|last4=P|first4=Gaulard|last5=C|first5=Copie-Bergman|last6=S|first6=Alkan|last7=Hy|first7=Wang|last8=Jx|first8=Cheng|last9=Cm|first9=Bacon|date=2013|title=Indolent T-cell lymphoproliferative disease of the gastrointestinal tract|url=https://pubmed.ncbi.nlm.nih.gov/24009234/|language=en|doi=10.1182/blood-2013-07-512830|pmc=PMC3837508|pmid=24009234}}</ref>
**Indolent, but chronic relapsing clinical course
**Indolent, but chronic relapsing clinical course


*'''Therapeutic Implications'''
*'''Therapeutic Implications'''
**Generally unresponsive to therapy<ref name=":1" />
**Generally unresponsive to therapy<ref name=":1">{{Cite journal|last=E|first=Margolskee|last2=V|first2=Jobanputra|last3=Sk|first3=Lewis|last4=B|first4=Alobeid|last5=Ph|first5=Green|last6=G|first6=Bhagat|date=2013|title=Indolent small intestinal CD4+ T-cell lymphoma is a distinct entity with unique biologic and clinical features|url=https://pubmed.ncbi.nlm.nih.gov/23861889/|language=en|doi=10.1371/journal.pone.0068343|pmc=PMC3701677|pmid=23861889}}</ref>
***The potential use of JAK-STAT inhibitors such as tofacinib and AZD1480 has not been formally tested
***The potential use of JAK-STAT inhibitors such as tofacinib and AZD1480 has not been formally tested


Line 312: Line 189:
{| class="wikitable sortable"
{| class="wikitable sortable"
|-
|-
!Chr #!!'''Gain, Loss, Amp, LOH'''!!'''Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]'''!!'''Relevant Gene(s)'''
!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
!'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T'''
!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
!'''Established Clinical Significance Per Guidelines - Yes or No (Source)'''
!Established Clinical Significance Per Guidelines - Yes or No (Source)
!'''Clinical Relevance Details/Other Notes'''
!Clinical Relevance Details/Other Notes
|-
|-
|<span class="blue-text">EXAMPLE:</span>
|<span class="blue-text">EXAMPLE:</span>
Line 362: Line 239:
|}
|}


<blockquote class='blockedit'>{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}}</blockquote>
<blockquote class="blockedit">{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}}</blockquote>


{| class="wikitable sortable"
{| class="wikitable sortable"
Line 412: Line 289:




<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref name=":1" /><blockquote class="blockedit">
<blockquote class="blockedit">{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref name=":1" /><blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
----
Line 428: Line 305:
!Chromosomal Pattern
!Chromosomal Pattern
!Molecular Pathogenesis
!Molecular Pathogenesis
!'''Prevalence -'''
!Prevalence -  
'''Common >20%, Recurrent 5-20% or Rare <5% (Disease)'''
Common >20%, Recurrent 5-20% or Rare <5% (Disease)
!'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T'''
!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
!'''Established Clinical Significance Per Guidelines - Yes or No (Source)'''
!Established Clinical Significance Per Guidelines - Yes or No (Source)
!'''Clinical Relevance Details/Other Notes'''
!Clinical Relevance Details/Other Notes
|-
|-
|<span class="blue-text">EXAMPLE:</span>
|<span class="blue-text">EXAMPLE:</span>
Line 458: Line 335:
|}
|}


<blockquote class='blockedit'>{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}</blockquote>
<blockquote class="blockedit">{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}</blockquote>


*  
*


<blockquote class="blockedit">
<blockquote class="blockedit">
Line 472: Line 349:
{| class="wikitable sortable"
{| class="wikitable sortable"
|-
|-
!Gene!!'''Genetic Alteration'''!!'''Tumor Suppressor Gene, Oncogene, Other'''!!'''Prevalence -'''
!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
'''Common >20%, Recurrent 5-20% or Rare <5% (Disease)'''
Common >20%, Recurrent 5-20% or Rare <5% (Disease)
!'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T  '''
!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T  
!'''Established Clinical Significance Per Guidelines - Yes or No (Source)'''
!Established Clinical Significance Per Guidelines - Yes or No (Source)
!'''Clinical Relevance Details/Other Notes'''
!Clinical Relevance Details/Other Notes
|-
|-
|<span class="blue-text">EXAMPLE:</span>''EGFR''
|<span class="blue-text">EXAMPLE:</span>''EGFR''
Line 514: Line 391:
|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.


<blockquote class='blockedit'>{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}}</blockquote>
<blockquote class="blockedit">{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}}</blockquote>




Line 526: Line 403:




<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref>{{Cite journal|last=Cr|first=Soderquist|last2=N|first2=Patel|last3=Vv|first3=Murty|last4=S|first4=Betman|last5=N|first5=Aggarwal|last6=Kh|first6=Young|last7=L|first7=Xerri|last8=R|first8=Leeman-Neill|last9=Sk|first9=Lewis|date=2020|title=Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract|url=https://pubmed.ncbi.nlm.nih.gov/31558678/|language=en|doi=10.3324/haematol.2019.230961|pmc=PMC7327650|pmid=31558678}}</ref><blockquote class="blockedit">
<blockquote class="blockedit">{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref>{{Cite journal|last=Cr|first=Soderquist|last2=N|first2=Patel|last3=Vv|first3=Murty|last4=S|first4=Betman|last5=N|first5=Aggarwal|last6=Kh|first6=Young|last7=L|first7=Xerri|last8=R|first8=Leeman-Neill|last9=Sk|first9=Lewis|date=2020|title=Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract|url=https://pubmed.ncbi.nlm.nih.gov/31558678/|language=en|doi=10.3324/haematol.2019.230961|pmc=PMC7327650|pmid=31558678}}</ref><blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
----
Line 563: Line 440:
|}
|}


<blockquote class='blockedit'>{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}}</blockquote>
<blockquote class="blockedit">{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}}</blockquote>




Line 569: Line 446:




<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref name=":0" /><blockquote class="blockedit">
<blockquote class="blockedit">{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref name=":0" /><blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
----
Line 601: Line 478:
(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span> <references />
(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span> <references />


'''
<br />


==Notes==
==Notes==
Line 610: Line 487:
          
          
<nowiki>*</nowiki>''Citation of this Page'': “Indolent T-cell lymphoma of the gastrointestinal tract”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Indolent_T-cell_lymphoma_of_the_gastrointestinal_tract</nowiki>.
<nowiki>*</nowiki>''Citation of this Page'': “Indolent T-cell lymphoma of the gastrointestinal tract”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Indolent_T-cell_lymphoma_of_the_gastrointestinal_tract</nowiki>.
[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases I]]
[[Category:HAEM5]]
[[Category:DISEASE]]
[[Category:Diseases I]]
Retrieved from "https://test.ccga.io/index.php/HAEM5:Indolent_T-cell_lymphoma_of_the_gastrointestinal_tract"